Winst gevend schreef op 15 september 2021 11:11:
"
Leniolisib is going to be quite a significant product compared to RUCONEST for our company going forward."
The European business becomes far more significant than it was in the years before, but it's also important to realize that we have the commercialization capabilities, and we're rolling out the commercialization capabilities across the entire European Union and Great Britain, of course, to make sure that we can launch leniolisib in a very swift way into the European Union and Great Britain. I think that's an important aspect here. That is as important, or maybe even more important, for the future of the European business. Because leniolisib is going to be quite a significant product compared to RUCONEST for our company going forward.
En nu maar hopen dat de resultaten goed genoeg zijn voor de aanvraag en goedkeuring
bij de EMA en FDA, dan gaan er een paar miljoen lachen om de 85 losse centen.
Stay tuned.............